07.11.16
Headquarters: Dublin, Ireland
twitter.com/Allergan
www.allergan.com
Headcount: 31,200
Year Established: 2015
Revenues: $15,071 (+124%)
Net Income: $3,683 (-$1,630 FY14)
R&D: $2,359 (+289%)
TOP SELLING DRUGS
In 2014 after Actavis acquired Allergan in a mega deal worth $66 billion it adopted the Allergan name. The deal was completed in March 2015 and the company’s portfolio was bolstered by the addition of Legacy Allergan’s therapeutic franchises in ophthalmology, neurosciences and medical aesthetics/dermatology/plastic surgery, complementing the its existing central nervous system, gastroenterology, women’s health and urology franchises.
The combined company benefited from Legacy Allergan’s global brand recognition and consumer awareness of key products, including Botox and Restasis. The transaction also expanded the its presence and market and product reach across many international markets, with strengthened commercial positions across Canada, Europe, Southeast Asia and other high-value growth markets, including China, India, the Middle East and Latin America.
The year will be remembered more though for the proposed merger of Pfizer and Allergan in November for a whopping $160 billion, a deal that would have created the largest pharma company in the world. But, the deal didn’t go through. It was called off at the last minute after a change in U.S. tax law and is discussed in more detail in Pfizer’s profile at the beginning of this report.
However, there were several other deals of note that did go through. One was the acquisition of Kythera Biopharmaceuticals for $2.1 billion. Kythera is focused on the discovery, development and commercialization of novel prescription aesthetic products. Its lead product, Kybella injection, is the first and only FDA-approved, non-surgical treatment for moderate to severe submental fullness, commonly referred to as double chin.
In another deal, Allergan acquired Auden Mckenzie, a company specializing in the development, licensing and marketing of niche generic medicines and proprietary brands in the UK and across Europe for approximately $500 million. The acquisition of Auden Mckenzie makes Actavis the number one supplier of generic pharmaceuticals in the UK and gives the company the number three position in the supply of UK pharmaceuticals.
With Ironwood Pharmaceuticals, Allergan struck a deal to acquire rights to Constella (linaclotide) in the EU, Switzerland, Turkey.
Allergan also acquired certain products in early stage development from Naurex, $571 million plus future contingent payments up to $1.1 billion. The deal expands Allergan’s pipeline with Naurex’s two leading product candidates GLYX-13 and NRX-1074, two compounds that utilize NMDA modulation as a potential new approach to the treatment of major depressive disorder (MDD).
Lastly, the company entered into an agreement with Merck to acquire the exclusive worldwide rights to Merck’s early development stage investigational small molecule oral calcitonin gene-related peptide receptor antagonists, which are being developed for the treatment and prevention of migraines for $250 million. Additionally, Merck is owed contingent payments based on commercial and development milestones of up to $965 million as well as royalties.
During the year Allergan entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals, a clinical stage biotechnology company, to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease.
twitter.com/Allergan
www.allergan.com
Headcount: 31,200
Year Established: 2015
Revenues: $15,071 (+124%)
Net Income: $3,683 (-$1,630 FY14)
R&D: $2,359 (+289%)
TOP SELLING DRUGS
Drug | Indication | 2015 Sales | (+/-%) |
Botox | chronic migraine, overactive bladder | $656 | n/a |
Restasis | dry eye | $365 | n/a |
Lumigan | ocular hypertension | $192 | n/a |
Namenda XR | Alzheimer’s disease | $190 | 27% |
Delzicol/Asaco | ulcerative colitis | $163 | 3% |
Bystolic | hypertension | $169 | 10% |
Alphagan/Combigan | glaucoma, ocular hypertension | $139 | n/a |
Linzess/Constella | irritable bowel syndrome | $131 | 39% |
In 2014 after Actavis acquired Allergan in a mega deal worth $66 billion it adopted the Allergan name. The deal was completed in March 2015 and the company’s portfolio was bolstered by the addition of Legacy Allergan’s therapeutic franchises in ophthalmology, neurosciences and medical aesthetics/dermatology/plastic surgery, complementing the its existing central nervous system, gastroenterology, women’s health and urology franchises.
The combined company benefited from Legacy Allergan’s global brand recognition and consumer awareness of key products, including Botox and Restasis. The transaction also expanded the its presence and market and product reach across many international markets, with strengthened commercial positions across Canada, Europe, Southeast Asia and other high-value growth markets, including China, India, the Middle East and Latin America.
The year will be remembered more though for the proposed merger of Pfizer and Allergan in November for a whopping $160 billion, a deal that would have created the largest pharma company in the world. But, the deal didn’t go through. It was called off at the last minute after a change in U.S. tax law and is discussed in more detail in Pfizer’s profile at the beginning of this report.
However, there were several other deals of note that did go through. One was the acquisition of Kythera Biopharmaceuticals for $2.1 billion. Kythera is focused on the discovery, development and commercialization of novel prescription aesthetic products. Its lead product, Kybella injection, is the first and only FDA-approved, non-surgical treatment for moderate to severe submental fullness, commonly referred to as double chin.
In another deal, Allergan acquired Auden Mckenzie, a company specializing in the development, licensing and marketing of niche generic medicines and proprietary brands in the UK and across Europe for approximately $500 million. The acquisition of Auden Mckenzie makes Actavis the number one supplier of generic pharmaceuticals in the UK and gives the company the number three position in the supply of UK pharmaceuticals.
With Ironwood Pharmaceuticals, Allergan struck a deal to acquire rights to Constella (linaclotide) in the EU, Switzerland, Turkey.
Allergan also acquired certain products in early stage development from Naurex, $571 million plus future contingent payments up to $1.1 billion. The deal expands Allergan’s pipeline with Naurex’s two leading product candidates GLYX-13 and NRX-1074, two compounds that utilize NMDA modulation as a potential new approach to the treatment of major depressive disorder (MDD).
Lastly, the company entered into an agreement with Merck to acquire the exclusive worldwide rights to Merck’s early development stage investigational small molecule oral calcitonin gene-related peptide receptor antagonists, which are being developed for the treatment and prevention of migraines for $250 million. Additionally, Merck is owed contingent payments based on commercial and development milestones of up to $965 million as well as royalties.
During the year Allergan entered into an exclusive licensing agreement with Mimetogen Pharmaceuticals, a clinical stage biotechnology company, to develop and commercialize tavilermide (MIM-D3), a topical formulation of a novel small molecule TrkA agonist for the treatment of dry eye disease.